2017•Journal of the Neurological SciencesRequires access

Safety and efficacy of fingolimod and natalizumab in multiple sclerosis after the failure of first-line therapy: Single center experience based on forty-four patients

Przemysław Puz, Anetta Lasek‐Bal

Open publisher page 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Natalizumab, Fingolimod, Glatiramer acetate, Multiple sclerosis, Medicine, Second-line therapy, First line therapy, Relapsing remitting

Back to paper search Browse research topics Original source

Safety and efficacy of fingolimod and natalizumab in multiple sclerosis after the failure of first-line therapy: Single center experience based on forty-four patients — Research Paper | ScholarLens